Identification

Name
Dapagliflozin
Accession Number
DB06292
Type
Small Molecule
Groups
Approved
Description

Dapagliflozin is indicated for the management of diabetes mellitus type 2, and functions to improve glycemic control in adults when combined with diet and exercise. Dapagliflozin is a sodium-glucose cotransporter 2 inhibitor, which prevents glucose reabsorption in the kidney. Using dapagliflozin leads to heavy glycosuria (glucose excretion in the urine), which can lead to weight loss and tiredness. Dapagliflozin was approved by the FDA on Jan 08, 2014. Dapagliflozin is not recommended for patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis.

Structure
Thumb
Synonyms
  • (2S,3R,4R,5S,6R)-2-(4-Chloro-3-(4-ethoxybenzyl)phenyl)-6- (hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
External IDs
BMS 512148 / BMS-512148
Product Ingredients
IngredientUNIICASInChI Key
Dapagliflozin propanediol monohydrate887K2391VH960404-48-2GOADIQFWSVMMRJ-UPGAGZFNSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
EdistrideTablet, film coated10 mgOralAstra Zeneca Ab2015-11-09Not applicableEu
EdistrideTablet, film coated5 mgOralAstra Zeneca Ab2015-11-09Not applicableEu
EdistrideTablet, film coated5 mgOralAstra Zeneca Ab2015-11-09Not applicableEu
EdistrideTablet, film coated10 mgOralAstra Zeneca Ab2015-11-09Not applicableEu
EdistrideTablet, film coated5 mgOralAstra Zeneca Ab2015-11-09Not applicableEu
EdistrideTablet, film coated5 mgOralAstra Zeneca Ab2015-11-09Not applicableEu
EdistrideTablet, film coated10 mgOralAstra Zeneca Ab2015-11-09Not applicableEu
EdistrideTablet, film coated10 mgOralAstra Zeneca Ab2015-11-09Not applicableEu
EdistrideTablet, film coated5 mgOralAstra Zeneca Ab2015-11-09Not applicableEu
EdistrideTablet, film coated10 mgOralAstra Zeneca Ab2015-11-09Not applicableEu
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
QternDapagliflozin (10 mg) + Saxagliptin (5 mg)TabletOralAstra ZenecaNot applicableNot applicableCanada
QternDapagliflozin (10 mg/1) + Saxagliptin hydrochloride (5 mg/1)Tablet, film coatedOralAstra Zeneca Lp2017-12-04Not applicableUs
QternDapagliflozin (5 mg) + Saxagliptin (5 mg)TabletOralAstra ZenecaNot applicableNot applicableCanada
XigduoDapagliflozin propanediol monohydrate (5 mg) + Metformin Hydrochloride (850 mg)Tablet, film coatedOralAstra Zeneca Ab2014-01-16Not applicableEu
XigduoDapagliflozin propanediol monohydrate (5 mg) + Metformin Hydrochloride (1000 mg)Tablet, film coatedOralAstra Zeneca Ab2014-01-16Not applicableEu
XigduoDapagliflozin (5 mg) + Metformin Hydrochloride (1000 mg)TabletOralAstra Zeneca2016-02-08Not applicableCanada
XigduoDapagliflozin propanediol monohydrate (5 mg) + Metformin Hydrochloride (1000 mg)Tablet, film coatedOralAstra Zeneca Ab2014-01-16Not applicableEu
XigduoDapagliflozin propanediol monohydrate (5 mg) + Metformin Hydrochloride (850 mg)Tablet, film coatedOralAstra Zeneca Ab2014-01-16Not applicableEu
XigduoDapagliflozin propanediol monohydrate (5 mg) + Metformin Hydrochloride (850 mg)Tablet, film coatedOralAstra Zeneca Ab2014-01-16Not applicableEu
XigduoDapagliflozin propanediol monohydrate (5 mg) + Metformin Hydrochloride (1000 mg)Tablet, film coatedOralAstra Zeneca Ab2014-01-16Not applicableEu
Categories
UNII
1ULL0QJ8UC
CAS number
461432-26-8
Weight
Average: 408.873
Monoisotopic: 408.133966239
Chemical Formula
C21H25ClO6
InChI Key
JVHXJTBJCFBINQ-ADAARDCZSA-N
InChI
InChI=1S/C21H25ClO6/c1-2-27-15-6-3-12(4-7-15)9-14-10-13(5-8-16(14)22)21-20(26)19(25)18(24)17(11-23)28-21/h3-8,10,17-21,23-26H,2,9,11H2,1H3/t17-,18-,19+,20-,21+/m1/s1
IUPAC Name
(2S,3R,4R,5S,6R)-2-{4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl}-6-(hydroxymethyl)oxane-3,4,5-triol
SMILES
CCOC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C=C1

Pharmacology

Indication

Dapagliflozin is indicated for adjunct management of glycemic control in patients with type 2 diabetes mellitus, in combination with diet and exercise.

Associated Conditions
Pharmacodynamics

Increases in the amount of glucose excreted in the urine were observed in healthy subjects and in patients with type 2 diabetes mellitus following the administration of dapagliflozin. A Dapagliflozin dose of 10 mg per day in patients with type 2 diabetes mellitus for 12 weeks resulted in excretion of approximately 70 grams of glucose in the urine per day at week 12. A near maximum glucose excretion was observed at the dapagliflozin daily dose of 20 mg. This urinary glucose excretion with dapagliflozin also results in increases in urinary volume.

Mechanism of action

A competitive inhibitor of the sodium-glucose transport subtype 2 protein, dapagliflozin blocks glucose reabsorption into the kidney, resulting in the elimination of blood glucose through the urine.

TargetActionsOrganism
ASodium/glucose cotransporter 2
antagonist
inhibitor
Human
Absorption

Cmax is about 1 hour. (Obtained from 6 adult men in a fasted state administered a 50mg dose). 1.6% of unchanged dapagliflozin was found in the urine. A high-fat meal (52% caloric content) had no significant effect on previous pharmacokinetic parameters.

Volume of distribution
Not Available
Protein binding

91%.

Metabolism

Dapagliflozin 3-O-glucuronide is the primary metabolite of dapagliflozin, with 61% of the dapagliflozin dose recovered in the urine as this metabolite. The metabolism of dapagliflozin is primarily mediated by UGT1A9-dependent glucuronide conjugation. The major metabolite, dapagliflozin 3-O-glucuronide, is not an SGLT2 inhibitor.

Route of elimination
Not Available
Half life

13.8 hours with the consumption of a 50 mg dose.

Clearance

Oral plasma clearance of 4.9 mL/min/kg, and a renal clearance of 5.6 mL/min.

Toxicity

Compared to placebo-treated patients, patients with moderate renal impairment treated with dapagliflozin did not have improvement in glycemic control and had more renal-related adverse reactions and more bone fractures; therefore, dapagliflozin should not be initiated in this population. Based on its mechanism of action, dapagliflozin is not expected to be effective in patients with severe renal impairment (eGFR less than 30 mL/min/1.73 m2) or ESRD.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
5-(2-methylpiperazine-1-sulfonyl)isoquinolineThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline.Experimental
AbemaciclibThe serum concentration of Dapagliflozin can be increased when it is combined with Abemaciclib.Approved, Investigational
AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Dapagliflozin.Approved, Investigational
AcemetacinThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Acemetacin.Approved, Experimental, Investigational
AcetaminophenThe serum concentration of Dapagliflozin can be increased when it is combined with Acetaminophen.Approved
AcetohexamideDapagliflozin may increase the hypoglycemic activities of Acetohexamide.Approved, Investigational, Withdrawn
Acetyl sulfisoxazoleThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Acetyl sulfisoxazole.Approved, Vet Approved
Acetylsalicylic acidAcetylsalicylic acid may increase the hypoglycemic activities of Dapagliflozin.Approved, Vet Approved
AfatinibThe serum concentration of Dapagliflozin can be increased when it is combined with Afatinib.Approved
AlaproclateAlaproclate may increase the hypoglycemic activities of Dapagliflozin.Experimental
AlbendazoleThe serum concentration of Dapagliflozin can be increased when it is combined with Albendazole.Approved, Vet Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Dapagliflozin.Approved
AlectinibThe serum concentration of Dapagliflozin can be increased when it is combined with Alectinib.Approved, Investigational
AlfentanilThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Alfentanil.Approved, Illicit
AliskirenThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Aliskiren.Approved, Investigational
AloxiprinAloxiprin may increase the hypoglycemic activities of Dapagliflozin.Experimental
AlphacetylmethadolThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Alphaprodine.Illicit
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Dapagliflozin.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Dapagliflozin.Approved
AmineptineAmineptine may decrease the hypoglycemic activities of Dapagliflozin.Illicit, Withdrawn
Aminosalicylic AcidAminosalicylic Acid may increase the hypoglycemic activities of Dapagliflozin.Approved
AmiodaroneThe serum concentration of Dapagliflozin can be increased when it is combined with Amiodarone.Approved, Investigational
AmitriptylineAmitriptyline may decrease the hypoglycemic activities of Dapagliflozin.Approved
AmitriptylinoxideAmitriptylinoxide may decrease the hypoglycemic activities of Dapagliflozin.Approved, Investigational
AmlodipineThe serum concentration of Dapagliflozin can be increased when it is combined with Amlodipine.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Dapagliflozin.Approved, Illicit
AmodiaquineThe serum concentration of Dapagliflozin can be increased when it is combined with Amodiaquine.Approved, Investigational
AmoxapineAmoxapine may decrease the hypoglycemic activities of Dapagliflozin.Approved
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Dapagliflozin.Approved, Investigational
AmprenavirThe metabolism of Dapagliflozin can be decreased when combined with Amprenavir.Approved, Investigational
AmsacrineThe serum concentration of Dapagliflozin can be increased when it is combined with Amsacrine.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Amyl Nitrite is combined with Dapagliflozin.Approved
AnnamycinThe serum concentration of Dapagliflozin can be increased when it is combined with Annamycin.Investigational
ApalutamideThe serum concentration of Dapagliflozin can be decreased when it is combined with Apalutamide.Approved, Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Dapagliflozin.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Dapagliflozin.Approved
AprepitantThe serum concentration of Dapagliflozin can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Dapagliflozin.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Dapagliflozin.Investigational
Arsenic trioxideThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Arsenic trioxide.Approved, Investigational
ArticaineThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Articaine.Approved
AsenapineThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Asenapine.Approved
AstemizoleThe serum concentration of Dapagliflozin can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe metabolism of Dapagliflozin can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Dapagliflozin.Approved
AtorvastatinThe serum concentration of Dapagliflozin can be increased when it is combined with Atorvastatin.Approved
AzelastineThe serum concentration of Dapagliflozin can be increased when it is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Azilsartan medoxomil.Approved, Investigational
AzithromycinThe serum concentration of Dapagliflozin can be increased when it is combined with Azithromycin.Approved
AzosemideThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Azosemide.Investigational
Bafilomycin A1The serum concentration of Dapagliflozin can be increased when it is combined with Bafilomycin A1.Experimental
Bafilomycin B1The serum concentration of Dapagliflozin can be increased when it is combined with Bafilomycin B1.Experimental
BalsalazideBalsalazide may increase the hypoglycemic activities of Dapagliflozin.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Dapagliflozin.Experimental
BarbitalBarbital may increase the hypotensive activities of Dapagliflozin.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Dapagliflozin.Approved
BenazeprilThe risk or severity of renal failure and hyperkalemia can be increased when Dapagliflozin is combined with Benazepril.Approved, Investigational
BenazeprilatThe risk or severity of renal failure and hyperkalemia can be increased when Dapagliflozin is combined with Benazeprilat.Experimental
BendroflumethiazideThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Bendroflumethiazide.Approved
BenmoxinBenmoxin may increase the orthostatic hypotensive activities of Dapagliflozin.Withdrawn
BenzquinamideThe serum concentration of Dapagliflozin can be increased when it is combined with Benzquinamide.Withdrawn
BenzthiazideThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Benzthiazide.Approved
Benzyl alcoholThe serum concentration of Dapagliflozin can be increased when it is combined with Benzyl alcohol.Approved
BepridilThe serum concentration of Dapagliflozin can be increased when it is combined with Bepridil.Approved, Withdrawn
BesifloxacinThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Besifloxacin.Approved
BetamethasoneThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Betamethasone.Approved, Vet Approved
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Dapagliflozin.Approved, Investigational
BezitramideThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Bezitramide.Experimental, Illicit, Withdrawn
BicalutamideThe serum concentration of Dapagliflozin can be increased when it is combined with Bicalutamide.Approved
Biricodar dicitrateThe serum concentration of Dapagliflozin can be increased when it is combined with Biricodar dicitrate.Investigational
BisacodylThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Bisacodyl.Approved
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Dapagliflozin.Approved
BisoxatinThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Bisoxatin.Approved
BoceprevirThe metabolism of Dapagliflozin can be decreased when combined with Boceprevir.Approved, Withdrawn
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Dapagliflozin.Approved, Investigational
BosentanThe serum concentration of Dapagliflozin can be decreased when it is combined with Bosentan.Approved, Investigational
Brefeldin AThe serum concentration of Dapagliflozin can be increased when it is combined with Brefeldin A.Experimental
BretyliumThe risk or severity of adverse effects can be increased when Bretylium is combined with Dapagliflozin.Approved
BrexpiprazoleThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Brexpiprazole.Approved, Investigational
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Dapagliflozin.Approved
BromocriptineThe serum concentration of Dapagliflozin can be increased when it is combined with Bromocriptine.Approved, Investigational
BumetanideThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Dapagliflozin.Approved, Investigational
BuprenorphineThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuserelinThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Buserelin.Approved, Investigational
BuspironeThe serum concentration of Dapagliflozin can be increased when it is combined with Buspirone.Approved, Investigational
ButorphanolThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Butorphanol.Approved, Illicit, Vet Approved
ButriptylineButriptyline may decrease the hypoglycemic activities of Dapagliflozin.Approved
CabazitaxelThe serum concentration of Dapagliflozin can be increased when it is combined with Cabazitaxel.Approved
CaffeineThe serum concentration of Dapagliflozin can be increased when it is combined with Caffeine.Approved
CanagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Canagliflozin.Approved
Candesartan cilexetilThe risk or severity of hypotension, hyperkalemia, and hypokalemia can be increased when Candesartan cilexetil is combined with Dapagliflozin.Approved
CaptoprilThe serum concentration of Dapagliflozin can be increased when it is combined with Captopril.Approved
CarbamazepineThe metabolism of Dapagliflozin can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumCarbaspirin calcium may increase the hypoglycemic activities of Dapagliflozin.Experimental, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Dapagliflozin.Approved, Investigational
CarboxymethylcelluloseThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Carboxymethylcellulose.Approved, Investigational
CarbutamideDapagliflozin may increase the hypoglycemic activities of Carbutamide.Experimental
CarfentanilThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Carfentanil.Illicit, Investigational, Vet Approved
CaroxazoneCaroxazone may increase the orthostatic hypotensive activities of Dapagliflozin.Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Dapagliflozin.Approved
CarvedilolThe serum concentration of Dapagliflozin can be increased when it is combined with Carvedilol.Approved, Investigational
Castor oilThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Castor oil.Approved, Investigational, Nutraceutical, Vet Approved
CefoperazoneThe serum concentration of Dapagliflozin can be increased when it is combined with Cefoperazone.Approved, Investigational
CeftriaxoneThe serum concentration of Dapagliflozin can be increased when it is combined with Ceftriaxone.Approved
CelecoxibThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Dapagliflozin can be increased when it is combined with Ceritinib.Approved
Chloramine-TThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Chloramine-T.Vet Approved
ChloroformThe serum concentration of Dapagliflozin can be increased when it is combined with Chloroform.Vet Approved
ChlorothiazideThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Chlorothiazide.Approved, Vet Approved
ChlorpromazineThe serum concentration of Dapagliflozin can be increased when it is combined with Chlorpromazine.Approved, Investigational, Vet Approved
ChlorpropamideDapagliflozin may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
ChlorprothixeneThe serum concentration of Dapagliflozin can be increased when it is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorsulfaquinoxalineThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Chlorsulfaquinoxaline.Investigational
ChlorthalidoneThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Chlorthalidone.Approved
CilazaprilThe risk or severity of renal failure and hyperkalemia can be increased when Dapagliflozin is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Dapagliflozin.Approved, Investigational
CinoxacinThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Cinoxacin.Approved, Investigational, Withdrawn
CiprofloxacinThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Ciprofloxacin.Approved, Investigational
CitalopramCitalopram may increase the hypoglycemic activities of Dapagliflozin.Approved
ClarithromycinThe metabolism of Dapagliflozin can be decreased when combined with Clarithromycin.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Dapagliflozin.Approved, Investigational
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Dapagliflozin.Approved, Investigational
ClofazimineThe serum concentration of Dapagliflozin can be increased when it is combined with Clofazimine.Approved, Investigational
ClofenamideThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Clofenamide.Experimental
ClomipramineClomipramine may decrease the hypoglycemic activities of Dapagliflozin.Approved, Investigational, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Dapagliflozin.Approved
ClopamideThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Clopamide.Experimental
ClorexoloneThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Clorexolone.Experimental
ClorsulonThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Clorsulon.Vet Approved
ClotrimazoleThe metabolism of Dapagliflozin can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Clozapine.Approved
CobicistatThe metabolism of Dapagliflozin can be decreased when combined with Cobicistat.Approved
CodeineThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Codeine.Approved, Illicit
ColchicineThe serum concentration of Dapagliflozin can be increased when it is combined with Colchicine.Approved
Concanamycin AThe serum concentration of Dapagliflozin can be increased when it is combined with Concanamycin A.Experimental
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Dapagliflozin.Approved, Investigational
CorticotropinThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Corticotropin.Approved, Investigational, Vet Approved
Cortisone acetateThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Cortisone acetate.Approved, Investigational
CrizotinibThe serum concentration of Dapagliflozin can be increased when it is combined with Crizotinib.Approved
CurcuminThe metabolism of Dapagliflozin can be decreased when combined with Curcumin.Approved, Investigational
CyclobenzaprineCyclobenzaprine may decrease the hypoglycemic activities of Dapagliflozin.Approved
CyclopenthiazideThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Cyclopenthiazide.Experimental
CyclosporineThe serum concentration of Dapagliflozin can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Cyclothiazide.Approved
Cyproterone acetateThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Cyproterone acetate.Approved, Investigational
DabrafenibThe serum concentration of Dapagliflozin can be decreased when it is combined with Dabrafenib.Approved, Investigational
DaclatasvirThe serum concentration of Dapagliflozin can be increased when it is combined with Daclatasvir.Approved, Investigational
DactinomycinThe serum concentration of Dapagliflozin can be increased when it is combined with Dactinomycin.Approved, Investigational
DanazolThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Danazol.Approved
DanthronThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Danthron.Approved, Investigational, Withdrawn
DapoxetineDapoxetine may increase the hypoglycemic activities of Dapagliflozin.Investigational
DarunavirThe metabolism of Dapagliflozin can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Dapagliflozin can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Dapagliflozin can be increased when it is combined with Daunorubicin.Approved
DeferasiroxThe serum concentration of Dapagliflozin can be decreased when it is combined with Deferasirox.Approved, Investigational
DelaprilThe risk or severity of renal failure and hyperkalemia can be increased when Dapagliflozin is combined with Delapril.Investigational
DelavirdineThe metabolism of Dapagliflozin can be decreased when combined with Delavirdine.Approved
DersalazineDersalazine may increase the hypoglycemic activities of Dapagliflozin.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Dapagliflozin.Approved
DesipramineDesipramine may decrease the hypoglycemic activities of Dapagliflozin.Approved, Investigational
DesmethylsertralineThe serum concentration of Dapagliflozin can be increased when it is combined with Desmethylsertraline.Experimental
DesogestrelThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Desogestrel.Approved
DesvenlafaxineDesvenlafaxine may increase the hypoglycemic activities of Dapagliflozin.Approved, Investigational
DexamethasoneThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Dexamethasone.Approved, Investigational, Vet Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Dapagliflozin.Approved, Vet Approved
DexniguldipineThe serum concentration of Dapagliflozin can be increased when it is combined with Dexniguldipine.Experimental
DextromoramideThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DexverapamilThe serum concentration of Dapagliflozin can be increased when it is combined with Dexverapamil.Experimental
DezocineThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Dezocine.Approved, Investigational
DiazoxideThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Diazoxide.Approved
DibenzepinDibenzepin may decrease the hypoglycemic activities of Dapagliflozin.Experimental
DiclofenamideThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Diclofenamide.Approved, Investigational
DienogestThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Dienogest.Approved
Diethyl etherThe serum concentration of Dapagliflozin can be increased when it is combined with Diethyl ether.Experimental
DifloxacinThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Difloxacin.Vet Approved
DiflunisalDiflunisal may increase the hypoglycemic activities of Dapagliflozin.Approved, Investigational
DihydrocodeineThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Dihydrocodeine.Approved, Illicit
DihydroergotamineThe serum concentration of Dapagliflozin can be increased when it is combined with Dihydroergotamine.Approved, Investigational
DihydroetorphineThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Dihydromorphine.Experimental, Illicit
DiltiazemThe metabolism of Dapagliflozin can be decreased when combined with Diltiazem.Approved, Investigational
DimetacrineDimetacrine may decrease the hypoglycemic activities of Dapagliflozin.Approved, Withdrawn
DinutuximabThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Dinutuximab.Approved, Investigational
DiphenoxylateThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Diphenoxylate.Approved, Illicit
DipyridamoleThe serum concentration of Dapagliflozin can be increased when it is combined with Dipyridamole.Approved
DisopyramideDapagliflozin may increase the hypoglycemic activities of Disopyramide.Approved
DocusateThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Docusate.Approved
DofequidarThe serum concentration of Dapagliflozin can be increased when it is combined with Dofequidar.Experimental, Investigational
DosulepinDosulepin may decrease the hypoglycemic activities of Dapagliflozin.Approved
DovitinibThe serum concentration of Dapagliflozin can be increased when it is combined with Dovitinib.Investigational
DoxazosinThe serum concentration of Dapagliflozin can be increased when it is combined with Doxazosin.Approved
DoxepinDoxepin may decrease the hypoglycemic activities of Dapagliflozin.Approved, Investigational
DoxycyclineThe metabolism of Dapagliflozin can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DPDPEThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with DPDPE.Experimental
DronabinolThe serum concentration of Dapagliflozin can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe serum concentration of Dapagliflozin can be increased when it is combined with Dronedarone.Approved
DrospirenoneThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Drospirenone.Approved
DuloxetineDapagliflozin may increase the orthostatic hypotensive activities of Duloxetine.Approved
EconazoleThe serum concentration of Dapagliflozin can be increased when it is combined with Econazole.Approved
EfavirenzThe metabolism of Dapagliflozin can be decreased when combined with Efavirenz.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Dapagliflozin.Approved, Investigational
ElacridarThe serum concentration of Dapagliflozin can be increased when it is combined with Elacridar.Investigational
EluxadolineThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Eluxadoline.Approved, Investigational
EmopamilThe serum concentration of Dapagliflozin can be increased when it is combined with Emopamil.Experimental
EmpagliflozinThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of renal failure and hyperkalemia can be increased when Dapagliflozin is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of renal failure and hyperkalemia can be increased when Dapagliflozin is combined with Enalaprilat.Approved
EnasidenibThe serum concentration of Dapagliflozin can be increased when it is combined with Enasidenib.Approved, Investigational
EnoxacinThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Enoxacin.Approved, Investigational
EnzalutamideThe serum concentration of Dapagliflozin can be decreased when it is combined with Enzalutamide.Approved
EpinephrineThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Epinephrine.Approved, Vet Approved
EpitizideThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Epitizide.Experimental
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Dapagliflozin.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Dapagliflozin.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Dapagliflozin.Approved
ErgonovineThe serum concentration of Dapagliflozin can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Dapagliflozin can be increased when it is combined with Ergotamine.Approved
ErlotinibThe serum concentration of Dapagliflozin can be increased when it is combined with Erlotinib.Approved, Investigational
ErythromycinThe serum concentration of Dapagliflozin can be increased when it is combined with Erythromycin.Approved, Investigational, Vet Approved
EscitalopramEscitalopram may increase the hypoglycemic activities of Dapagliflozin.Approved, Investigational
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Dapagliflozin.Approved
EsomeprazoleThe serum concentration of Dapagliflozin can be increased when it is combined with Esomeprazole.Approved, Investigational
EstradiolThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Estradiol.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Dapagliflozin can be increased when it is combined with Estramustine.Approved, Investigational
Estrone sulfateThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Estrone sulfate.Approved
Etacrynic acidThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Etacrynic acid.Approved, Investigational
Ethinyl EstradiolThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Ethinyl Estradiol.Approved
EthoxzolamideThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Ethoxzolamide.Withdrawn
EthylmorphineThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Ethylmorphine.Approved, Illicit
Ethynodiol diacetateThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Ethynodiol diacetate.Approved
EtonogestrelThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Etonogestrel.Approved, Investigational
EtoposideThe serum concentration of Dapagliflozin can be increased when it is combined with Etoposide.Approved
EtorphineThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Etorphine.Illicit, Vet Approved
EtravirineThe serum concentration of Dapagliflozin can be decreased when it is combined with Etravirine.Approved
EverolimusThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Everolimus.Approved
FelodipineThe serum concentration of Dapagliflozin can be increased when it is combined with Felodipine.Approved, Investigational
FenofibrateThe serum concentration of Dapagliflozin can be increased when it is combined with Fenofibrate.Approved
FenoldopamThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Dapagliflozin.Approved
FenquizoneThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Fenquizone.Experimental
FentanylThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Dapagliflozin.Approved, Investigational
FleroxacinThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Fleroxacin.Approved
FluconazoleThe serum concentration of Dapagliflozin can be increased when it is combined with Fluconazole.Approved, Investigational
FludrocortisoneThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Fludrocortisone.Approved, Investigational
FlumequineThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Flumequine.Withdrawn
FluoxetineThe serum concentration of Dapagliflozin can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FluoxymesteroneFluoxymesterone may increase the hypoglycemic activities of Dapagliflozin.Approved, Illicit
FlupentixolThe serum concentration of Dapagliflozin can be increased when it is combined with Flupentixol.Approved, Investigational, Withdrawn
FluphenazineThe serum concentration of Dapagliflozin can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Dapagliflozin can be increased when it is combined with Flurazepam.Approved, Illicit, Investigational
FluvoxamineThe serum concentration of Dapagliflozin can be increased when it is combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Dapagliflozin can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe risk or severity of renal failure and hyperkalemia can be increased when Dapagliflozin is combined with Fosinopril.Approved
FosinoprilatThe risk or severity of renal failure and hyperkalemia can be increased when Dapagliflozin is combined with Fosinoprilat.Experimental
FosphenytoinThe metabolism of Dapagliflozin can be increased when combined with Fosphenytoin.Approved, Investigational
FurazolidoneFurazolidone may increase the orthostatic hypotensive activities of Dapagliflozin.Approved, Investigational, Vet Approved
FurosemideThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Dapagliflozin can be increased when it is combined with Fusidic Acid.Approved, Investigational
GallopamilThe serum concentration of Dapagliflozin can be increased when it is combined with Gallopamil.Investigational
GarenoxacinThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Garenoxacin.Investigational
GatifloxacinThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Gatifloxacin.Approved, Investigational
GefitinibThe serum concentration of Dapagliflozin can be increased when it is combined with Gefitinib.Approved, Investigational
GemifloxacinThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Gemifloxacin.Approved, Investigational
GenisteinThe serum concentration of Dapagliflozin can be increased when it is combined with Genistein.Investigational
GlecaprevirThe serum concentration of Dapagliflozin can be increased when it is combined with Glecaprevir.Approved, Investigational
GlibornurideDapagliflozin may increase the hypoglycemic activities of Glibornuride.Investigational, Withdrawn
GliclazideDapagliflozin may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideDapagliflozin may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideDapagliflozin may increase the hypoglycemic activities of Glipizide.Approved, Investigational
GliquidoneDapagliflozin may increase the hypoglycemic activities of Gliquidone.Approved, Investigational
GlisoxepideDapagliflozin may increase the hypoglycemic activities of Glisoxepide.Investigational
GLPG-0492GLPG-0492 may increase the hypoglycemic activities of Dapagliflozin.Investigational
GlyburideDapagliflozin may increase the hypoglycemic activities of Glyburide.Approved
GlycerinThe serum concentration of Dapagliflozin can be increased when it is combined with Glycerin.Approved, Investigational
GlycodiazineThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Glycodiazine.Approved, Investigational
GoserelinThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Goserelin.Approved
Gramicidin DThe serum concentration of Dapagliflozin can be increased when it is combined with Gramicidin D.Approved
GrepafloxacinThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Grepafloxacin.Approved, Investigational, Withdrawn
GuacetisalGuacetisal may increase the hypoglycemic activities of Dapagliflozin.Experimental
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Dapagliflozin.Approved, Investigational
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Dapagliflozin.Approved, Vet Approved
HarmalineHarmaline may increase the orthostatic hypotensive activities of Dapagliflozin.Experimental
HeroinThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Heroin.Approved, Illicit, Investigational
HexobarbitalHexobarbital may increase the hypotensive activities of Dapagliflozin.Approved
HistrelinThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Histrelin.Approved
HM-30181The serum concentration of Dapagliflozin can be increased when it is combined with HM-30181.Experimental
HycanthoneThe serum concentration of Dapagliflozin can be increased when it is combined with Hycanthone.Approved, Investigational
HydracarbazineHydracarbazine may increase the orthostatic hypotensive activities of Dapagliflozin.Experimental
HydralazineThe risk or severity of adverse effects can be increased when Hydralazine is combined with Dapagliflozin.Approved
HydrochlorothiazideThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Hydrocodone.Approved, Illicit
HydrocortisoneThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Hydroflumethiazide.Approved, Investigational
HydromorphoneThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Hydromorphone.Approved, Illicit
HydroxychloroquineThe serum concentration of Dapagliflozin can be increased when it is combined with Hydroxychloroquine.Approved
HydroxyfasudilThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Hydroxyfasudil.Experimental
Hydroxyprogesterone caproateThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Hydroxyprogesterone caproate.Approved, Investigational
IbuprofenThe serum concentration of Dapagliflozin can be increased when it is combined with Ibuprofen.Approved
IdelalisibThe metabolism of Dapagliflozin can be decreased when combined with Idelalisib.Approved
IloperidoneThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Iloperidone.Approved
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Dapagliflozin.Approved, Investigational
ImatinibThe serum concentration of Dapagliflozin can be increased when it is combined with Imatinib.Approved
ImidaprilThe risk or severity of renal failure and hyperkalemia can be increased when Dapagliflozin is combined with Imidapril.Investigational
ImipramineImipramine may decrease the hypoglycemic activities of Dapagliflozin.Approved
Imipramine oxideImipramine oxide may decrease the hypoglycemic activities of Dapagliflozin.Experimental
IndalpineIndalpine may increase the hypoglycemic activities of Dapagliflozin.Investigational, Withdrawn
IndapamideThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Indapamide.Approved
IndinavirThe metabolism of Dapagliflozin can be decreased when combined with Indinavir.Approved
IndomethacinThe serum concentration of Dapagliflozin can be increased when it is combined with Indomethacin.Approved, Investigational
IndoraminThe risk or severity of adverse effects can be increased when Indoramin is combined with Dapagliflozin.Withdrawn
Insulin AspartDapagliflozin may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DegludecDapagliflozin may increase the hypoglycemic activities of Insulin Degludec.Approved
Insulin DetemirDapagliflozin may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineDapagliflozin may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineDapagliflozin may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanDapagliflozin may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproDapagliflozin may increase the hypoglycemic activities of Insulin Lispro.Approved
Insulin peglisproDapagliflozin may increase the hypoglycemic activities of Insulin peglispro.Investigational
Insulin PorkDapagliflozin may increase the hypoglycemic activities of Insulin Pork.Approved
IprindoleIprindole may decrease the hypoglycemic activities of Dapagliflozin.Experimental
IproniazidIproniazid may increase the orthostatic hypotensive activities of Dapagliflozin.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Dapagliflozin.Approved, Investigational
IsavuconazoleThe serum concentration of Dapagliflozin can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe serum concentration of Dapagliflozin can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the orthostatic hypotensive activities of Dapagliflozin.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Dapagliflozin.Approved, Vet Approved
IsoniazidThe metabolism of Dapagliflozin can be decreased when combined with Isoniazid.Approved, Investigational
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Dapagliflozin.Approved, Investigational
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Dapagliflozin.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe serum concentration of Dapagliflozin can be increased when it is combined with Isradipine.Approved, Investigational
ItraconazoleThe metabolism of Dapagliflozin can be decreased when combined with Itraconazole.Approved, Investigational
IvermectinThe serum concentration of Dapagliflozin can be increased when it is combined with Ivermectin.Approved, Investigational, Vet Approved
IvosidenibThe serum concentration of Dapagliflozin can be increased when it is combined with Ivosidenib.Approved, Investigational
KetobemidoneThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Ketobemidone.Approved, Investigational
KetoconazoleThe metabolism of Dapagliflozin can be decreased when combined with Ketoconazole.Approved, Investigational
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Dapagliflozin.Approved
LacidipineDapagliflozin may increase the hypotensive activities of Lacidipine.Approved, Investigational
LactitolThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Lactitol.Investigational
LactuloseThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Lactulose.Approved
LaniquidarThe serum concentration of Dapagliflozin can be increased when it is combined with Laniquidar.Investigational
LanreotideThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Lanreotide.Approved
LansoprazoleThe serum concentration of Dapagliflozin can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Dapagliflozin can be increased when it is combined with Lapatinib.Approved, Investigational
LedipasvirThe serum concentration of Dapagliflozin can be increased when it is combined with Ledipasvir.Approved
LercanidipineThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Dapagliflozin.Approved, Investigational
LetermovirThe serum concentration of Dapagliflozin can be increased when it is combined with Letermovir.Approved, Investigational
LeuprolideThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Leuprolide.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Levobunolol is combined with Dapagliflozin.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Dapagliflozin.Approved, Investigational
LevodopaDapagliflozin may increase the orthostatic hypotensive activities of Levodopa.Approved
LevofloxacinThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Levofloxacin.Approved, Investigational
Levomethadyl AcetateThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the hypoglycemic activities of Dapagliflozin.Approved, Investigational
LevonorgestrelThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Levonorgestrel.Approved, Investigational
LevorphanolThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Levorphanol.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Dapagliflozin.Approved, Investigational
LidocaineThe serum concentration of Dapagliflozin can be increased when it is combined with Lidocaine.Approved, Vet Approved
LinaclotideThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Linaclotide.Approved
LinagliptinThe serum concentration of Dapagliflozin can be increased when it is combined with Linagliptin.Approved
LinezolidLinezolid may increase the orthostatic hypotensive activities of Dapagliflozin.Approved, Investigational
Lipoic AcidLipoic Acid may increase the hypoglycemic activities of Dapagliflozin.Approved, Investigational, Nutraceutical
LisinoprilThe risk or severity of renal failure and hyperkalemia can be increased when Dapagliflozin is combined with Lisinopril.Approved, Investigational
LofentanilThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Lofentanil.Illicit
LofepramineLofepramine may decrease the hypoglycemic activities of Dapagliflozin.Experimental
LofexidineThe risk or severity of adverse effects can be increased when Lofexidine is combined with Dapagliflozin.Approved, Investigational
LomefloxacinThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Lomefloxacin.Approved, Investigational
LomerizineThe serum concentration of Dapagliflozin can be increased when it is combined with Lomerizine.Experimental
LomitapideThe serum concentration of Dapagliflozin can be increased when it is combined with Lomitapide.Approved, Investigational
LonafarnibThe serum concentration of Dapagliflozin can be increased when it is combined with Lonafarnib.Investigational
LoperamideThe serum concentration of Dapagliflozin can be increased when it is combined with Loperamide.Approved
LopinavirThe metabolism of Dapagliflozin can be decreased when combined with Lopinavir.Approved
LoratadineThe serum concentration of Dapagliflozin can be increased when it is combined with Loratadine.Approved, Investigational
LorpiprazoleThe serum concentration of Dapagliflozin can be increased when it is combined with Lorpiprazole.Approved
LosartanThe serum concentration of Dapagliflozin can be increased when it is combined with Losartan.Approved
LovastatinThe serum concentration of Dapagliflozin can be increased when it is combined with Lovastatin.Approved, Investigational
LoxapineThe serum concentration of Dapagliflozin can be increased when it is combined with Loxapine.Approved
LubiprostoneThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Lubiprostone.Approved, Investigational
LuliconazoleThe serum concentration of Dapagliflozin can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Dapagliflozin can be decreased when it is combined with Lumacaftor.Approved
LurasidoneThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Lurasidone.Approved, Investigational
LusutrombopagThe serum concentration of Dapagliflozin can be increased when it is combined with Lusutrombopag.Approved, Investigational
MafenideThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Mafenide.Approved, Vet Approved
Magnesium carbonateThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Magnesium carbonate.Approved, Investigational
Magnesium citrateThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Magnesium citrate.Approved
Magnesium hydroxideThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Magnesium hydroxide.Approved, Investigational
Magnesium oxideThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Magnesium oxide.Approved
Magnesium peroxideThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Magnesium peroxide.Experimental
Magnesium sulfateThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Magnesium sulfate.Approved, Investigational, Vet Approved
MannitolThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Mannitol.Approved, Investigational
MebanazineMebanazine may increase the orthostatic hypotensive activities of Dapagliflozin.Withdrawn
MebutizideThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Mebutizide.Experimental
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Dapagliflozin.Approved, Investigational
MecaserminDapagliflozin may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
MedrogestoneThe serum concentration of Dapagliflozin can be decreased when it is combined with Medrogestone.Approved
Medroxyprogesterone acetateThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Medroxyprogesterone acetate.Approved, Investigational
MefloquineThe serum concentration of Dapagliflozin can be increased when it is combined with Mefloquine.Approved, Investigational
MefrusideThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Mefruside.Experimental
Megestrol acetateThe serum concentration of Dapagliflozin can be increased when it is combined with Megestrol acetate.Approved, Investigational, Vet Approved
MelitracenMelitracen may decrease the hypoglycemic activities of Dapagliflozin.Experimental, Investigational
MeptazinolThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Meptazinol.Experimental
MesalazineMesalazine may increase the hypoglycemic activities of Dapagliflozin.Approved
MesteroloneMesterolone may increase the hypoglycemic activities of Dapagliflozin.Experimental
MestranolThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Mestranol.Approved
MetahexamideDapagliflozin may increase the hypoglycemic activities of Metahexamide.Experimental
MethadoneThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Methadone.Approved
Methadyl AcetateThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Methadyl Acetate.Approved, Illicit
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Dapagliflozin.Approved
MethohexitalMethohexital may increase the hypotensive activities of Dapagliflozin.Approved
MethotrimeprazineThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Methotrimeprazine.Approved, Investigational
MethyclothiazideThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Methyclothiazide.Approved
Methyl celluloseThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Methyl cellulose.Approved
Methyl salicylateMethyl salicylate may increase the hypoglycemic activities of Dapagliflozin.Approved, Vet Approved
MethyldopaThe risk or severity of adverse effects can be increased when Methyldopa is combined with Dapagliflozin.Approved
Methylene blueMethylene blue may increase the orthostatic hypotensive activities of Dapagliflozin.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Dapagliflozin.Approved
MethylprednisoloneThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Methylprednisolone.Approved, Vet Approved
MethyltestosteroneMethyltestosterone may increase the hypoglycemic activities of Dapagliflozin.Approved
MeticraneThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Meticrane.Experimental
MetipranololThe risk or severity of adverse effects can be increased when Metipranolol is combined with Dapagliflozin.Approved
MetolazoneThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Metolazone.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Dapagliflozin.Approved, Investigational
MetronidazoleThe serum concentration of Dapagliflozin can be increased when it is combined with Metronidazole.Approved
MibefradilThe metabolism of Dapagliflozin can be decreased when combined with Mibefradil.Investigational, Withdrawn
MiconazoleThe serum concentration of Dapagliflozin can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Dapagliflozin can be increased when it is combined with Midazolam.Approved, Illicit
MifepristoneThe serum concentration of Dapagliflozin can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranMilnacipran may increase the hypoglycemic activities of Dapagliflozin.Approved, Investigational
MinaprineMinaprine may increase the orthostatic hypotensive activities of Dapagliflozin.Approved
Mineral oilThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Mineral oil.Approved, Vet Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Dapagliflozin.Approved, Investigational
MitotaneThe serum concentration of Dapagliflozin can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Dapagliflozin can be increased when it is combined with Mitoxantrone.Approved, Investigational
MoclobemideMoclobemide may increase the orthostatic hypotensive activities of Dapagliflozin.Approved, Investigational
ModafinilThe serum concentration of Dapagliflozin can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilThe risk or severity of renal failure and hyperkalemia can be increased when Dapagliflozin is combined with Moexipril.Approved
MonensinThe serum concentration of Dapagliflozin can be increased when it is combined with Monensin.Vet Approved
MorphineThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Morphine.Approved, Investigational
MoxifloxacinThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Moxifloxacin.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Moxonidine is combined with Dapagliflozin.Approved, Investigational
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Dapagliflozin.Approved, Investigational
NadololThe risk or severity of adverse effects can be increased when Nadolol is combined with Dapagliflozin.Approved
NafcillinThe serum concentration of Dapagliflozin can be decreased when it is combined with Nafcillin.Approved, Investigational
NalbuphineThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Nalbuphine.Approved
Nalidixic AcidThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Nalidixic Acid.Approved, Investigational
NaloxoneThe metabolism of Dapagliflozin can be decreased when combined with Naloxone.Approved, Vet Approved
NaltrexoneThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Naltrexone.Approved, Investigational, Vet Approved
NandroloneNandrolone may increase the hypoglycemic activities of Dapagliflozin.Experimental, Investigational
Nandrolone decanoateNandrolone decanoate may increase the hypoglycemic activities of Dapagliflozin.Approved, Illicit
NateglinideDapagliflozin may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NebivololThe risk or severity of adverse effects can be increased when Nebivolol is combined with Dapagliflozin.Approved, Investigational
NefazodoneThe metabolism of Dapagliflozin can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Dapagliflozin can be decreased when combined with Nelfinavir.Approved
NemonoxacinThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Nemonoxacin.Investigational
NeratinibThe serum concentration of Dapagliflozin can be increased when it is combined with Neratinib.Approved, Investigational
NesiritideThe risk or severity of adverse effects can be increased when Nesiritide is combined with Dapagliflozin.Approved, Investigational
NetupitantThe serum concentration of Dapagliflozin can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe metabolism of Dapagliflozin can be increased when combined with Nevirapine.Approved
NiacinThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Niacin.Approved, Investigational, Nutraceutical
NialamideNialamide may increase the orthostatic hypotensive activities of Dapagliflozin.Withdrawn
NicardipineThe serum concentration of Dapagliflozin can be increased when it is combined with Nicardipine.Approved, Investigational
NicomorphineThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Nicomorphine.Experimental
NicorandilNicorandil may increase the hypotensive activities of Dapagliflozin.Approved, Investigational
NifedipineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Dapagliflozin.Approved
NigericinThe serum concentration of Dapagliflozin can be increased when it is combined with Nigericin.Experimental
NiguldipineThe serum concentration of Dapagliflozin can be increased when it is combined with Niguldipine.Experimental
NilotinibThe metabolism of Dapagliflozin can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipineThe risk or severity of adverse effects can be increased when Nilvadipine is combined with Dapagliflozin.Approved, Investigational
NimodipineThe serum concentration of Dapagliflozin can be increased when it is combined with Nimodipine.Approved, Investigational
NisoldipineThe serum concentration of Dapagliflozin can be increased when it is combined with Nisoldipine.Approved
NitrendipineThe serum concentration of Dapagliflozin can be increased when it is combined with Nitrendipine.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Dapagliflozin.Approved
NitroaspirinNitroaspirin may increase the hypoglycemic activities of Dapagliflozin.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Dapagliflozin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Dapagliflozin.Approved, Investigational
Nitrous acidThe risk or severity of adverse effects can be increased when Nitrous acid is combined with Dapagliflozin.Approved, Investigational
NN344Dapagliflozin may increase the hypoglycemic activities of NN344.Investigational
NorethisteroneThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Norethisterone.Approved
NorfloxacinThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Norfloxacin.Approved
NorgestimateThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Norgestimate.Approved, Investigational
NormethadoneThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Normethadone.Approved, Illicit
NortriptylineNortriptyline may decrease the hypoglycemic activities of Dapagliflozin.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Dapagliflozin.Approved, Investigational
OctamoxinOctamoxin may increase the orthostatic hypotensive activities of Dapagliflozin.Withdrawn
OctreotideThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Octreotide.Approved, Investigational
OfloxacinThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Ofloxacin.Approved
OlanzapineThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Olanzapine.Approved, Investigational
OlaparibThe metabolism of Dapagliflozin can be decreased when combined with Olaparib.Approved
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Dapagliflozin.Approved, Investigational
OlsalazineOlsalazine may increase the hypoglycemic activities of Dapagliflozin.Approved
OmapatrilatThe risk or severity of renal failure and hyperkalemia can be increased when Dapagliflozin is combined with Omapatrilat.Investigational
OmeprazoleThe serum concentration of Dapagliflozin can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
ONT-093The serum concentration of Dapagliflozin can be increased when it is combined with ONT-093.Investigational
OpipramolOpipramol may decrease the hypoglycemic activities of Dapagliflozin.Investigational
OpiumThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Opium.Approved, Illicit
OrbifloxacinThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Orbifloxacin.Vet Approved
OsimertinibThe serum concentration of Dapagliflozin can be increased when it is combined with Osimertinib.Approved
OxandroloneOxandrolone may increase the hypoglycemic activities of Dapagliflozin.Approved, Investigational
OxaprotilineOxaprotiline may decrease the hypoglycemic activities of Dapagliflozin.Experimental
Oxolinic acidThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Oxolinic acid.Experimental
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Dapagliflozin.Approved
OxycodoneThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Oxycodone.Approved, Illicit, Investigational
OxymetholoneOxymetholone may increase the hypoglycemic activities of Dapagliflozin.Approved, Illicit
OxymorphoneThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Oxymorphone.Approved, Investigational, Vet Approved
OxyphenisatinThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Oxyphenisatin.Investigational, Withdrawn
PaclitaxelThe serum concentration of Dapagliflozin can be increased when it is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Dapagliflozin can be increased when it is combined with Palbociclib.Approved, Investigational
PaliperidoneThe serum concentration of Dapagliflozin can be increased when it is combined with Paliperidone.Approved
PantoprazoleThe serum concentration of Dapagliflozin can be increased when it is combined with Pantoprazole.Approved
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Dapagliflozin.Approved, Investigational
PargylinePargyline may increase the orthostatic hypotensive activities of Dapagliflozin.Approved
ParitaprevirThe serum concentration of Dapagliflozin can be increased when it is combined with Paritaprevir.Approved, Investigational
ParoxetineThe serum concentration of Dapagliflozin can be increased when it is combined with Paroxetine.Approved, Investigational
PasireotideThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Pasireotide.Approved
PazufloxacinThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Pazufloxacin.Investigational
PefloxacinThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Pefloxacin.Approved
PegvisomantPegvisomant may increase the hypoglycemic activities of Dapagliflozin.Approved
PenbutololThe risk or severity of adverse effects can be increased when Penbutolol is combined with Dapagliflozin.Approved, Investigational
PentaerithritylThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Pentaerithrityl.Experimental
PentamidineThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Pentamidine.Approved, Investigational
PentazocineThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Pentazocine.Approved, Vet Approved
PentobarbitalPentobarbital may increase the hypotensive activities of Dapagliflozin.Approved, Investigational, Vet Approved
PerindoprilThe risk or severity of renal failure and hyperkalemia can be increased when Dapagliflozin is combined with Perindopril.Approved
PerindoprilatThe risk or severity of renal failure and hyperkalemia can be increased when Dapagliflozin is combined with Perindoprilat.Experimental
PethidineThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Pethidine.Approved
PhenazocineThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Phenazocine.Experimental
PhenelzinePhenelzine may increase the orthostatic hypotensive activities of Dapagliflozin.Approved
PheniprazinePheniprazine may increase the orthostatic hypotensive activities of Dapagliflozin.Withdrawn
PhenobarbitalPhenobarbital may increase the hypotensive activities of Dapagliflozin.Approved, Investigational
PhenolphthaleinThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Phenolphthalein.Approved, Withdrawn
PhenoperidineThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Phenoperidine.Experimental
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Dapagliflozin.Approved
PhenoxypropazinePhenoxypropazine may increase the orthostatic hypotensive activities of Dapagliflozin.Withdrawn
PhentolamineThe risk or severity of adverse effects can be increased when Phentolamine is combined with Dapagliflozin.Approved
Phenyl aminosalicylatePhenyl aminosalicylate may increase the hypoglycemic activities of Dapagliflozin.Approved
PhenytoinThe metabolism of Dapagliflozin can be increased when combined with Phenytoin.Approved, Vet Approved
PhthalylsulfathiazoleThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Phthalylsulfathiazole.Experimental
PibrentasvirThe serum concentration of Dapagliflozin can be increased when it is combined with Pibrentasvir.Approved, Investigational
Picosulfuric acidThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Picosulfuric acid.Approved
PimozideThe serum concentration of Dapagliflozin can be increased when it is combined with Pimozide.Approved
PindololThe risk or severity of adverse effects can be increased when Pindolol is combined with Dapagliflozin.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Dapagliflozin.Approved, Investigational
Pipemidic acidThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Pipemidic acid.Experimental
PiperazineThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Piperazine.Approved, Vet Approved
PipotiazineThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Pipotiazine.Approved, Investigational
PiretanideThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Piretanide.Approved
PiritramideThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Piritramide.Approved, Investigational
PirlindolePirlindole may increase the orthostatic hypotensive activities of Dapagliflozin.Approved
Piromidic acidThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Piromidic acid.Experimental
PitolisantThe serum concentration of Dapagliflozin can be decreased when it is combined with Pitolisant.Approved, Investigational
PivhydrazinePivhydrazine may increase the orthostatic hypotensive activities of Dapagliflozin.Withdrawn
Plantago seedThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Plantago seed.Approved, Investigational
PlecanatideThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Plecanatide.Approved, Investigational
PolycarbophilThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Polycarbophil.Approved
Polyethylene glycolThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Polyethylene glycol.Approved, Vet Approved
PolythiazideThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Polythiazide.Approved
PonatinibThe serum concentration of Dapagliflozin can be increased when it is combined with Ponatinib.Approved, Investigational
PosaconazoleThe metabolism of Dapagliflozin can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
Potassium acetateThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Potassium acetate.Approved, Investigational
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Dapagliflozin.Approved, Investigational
PrazosinThe serum concentration of Dapagliflozin can be increased when it is combined with Prazosin.Approved
PrednisoloneThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Prednisolone.Approved, Vet Approved
PrednisoneThe serum concentration of Dapagliflozin can be increased when it is combined with Prednisone.Approved, Vet Approved
PregabalinThe risk or severity of heart failure can be increased when Pregabalin is combined with Dapagliflozin.Approved, Illicit, Investigational
PrimaquineThe serum concentration of Dapagliflozin can be increased when it is combined with Primaquine.Approved
PrimidonePrimidone may increase the hypotensive activities of Dapagliflozin.Approved, Vet Approved
ProbenecidThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Probenecid.Approved, Investigational
ProgesteroneThe serum concentration of Dapagliflozin can be increased when it is combined with Progesterone.Approved, Vet Approved
PromethazineThe serum concentration of Dapagliflozin can be increased when it is combined with Promethazine.Approved, Investigational
PropafenoneThe serum concentration of Dapagliflozin can be increased when it is combined with Propafenone.Approved
PropofolThe serum concentration of Dapagliflozin can be increased when it is combined with Propofol.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Dapagliflozin.Approved, Investigational
ProtriptylineProtriptyline may decrease the hypoglycemic activities of Dapagliflozin.Approved
PrucaloprideThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Prucalopride.Approved
PrulifloxacinThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Prulifloxacin.Investigational
QuercetinThe serum concentration of Dapagliflozin can be increased when it is combined with Quercetin.Experimental, Investigational
QuetiapineThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Quetiapine.Approved
QuinacrineThe serum concentration of Dapagliflozin can be increased when it is combined with Quinacrine.Approved, Investigational
QuinaprilThe risk or severity of renal failure and hyperkalemia can be increased when Dapagliflozin is combined with Quinapril.Approved, Investigational
QuinaprilatThe risk or severity of renal failure and hyperkalemia can be increased when Dapagliflozin is combined with Quinaprilat.Experimental
QuinethazoneThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Quinethazone.Approved
QuinidineThe serum concentration of Dapagliflozin can be increased when it is combined with Quinidine.Approved, Investigational
QuinineThe metabolism of Dapagliflozin can be increased when combined with Quinine.Approved
QuinupramineQuinupramine may decrease the hypoglycemic activities of Dapagliflozin.Experimental
RamiprilThe risk or severity of renal failure and hyperkalemia can be increased when Dapagliflozin is combined with Ramipril.Approved
RamiprilatThe risk or severity of renal failure and hyperkalemia can be increased when Dapagliflozin is combined with Ramiprilat.Experimental
RanitidineThe serum concentration of Dapagliflozin can be increased when it is combined with Ranitidine.Approved
RasagilineRasagiline may increase the orthostatic hypotensive activities of Dapagliflozin.Approved
ReboxetineThe serum concentration of Dapagliflozin can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Dapagliflozin can be increased when it is combined with Regorafenib.Approved
RemifentanilThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Remifentanil.Approved
RepaglinideDapagliflozin may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
RescinnamineThe risk or severity of renal failure and hyperkalemia can be increased when Dapagliflozin is combined with Rescinnamine.Approved
ReserpineThe serum concentration of Dapagliflozin can be increased when it is combined with Reserpine.Approved, Investigational
Reversin 121The serum concentration of Dapagliflozin can be increased when it is combined with Reversin 121.Experimental
RifampicinThe metabolism of Dapagliflozin can be increased when combined with Rifampicin.Approved
RifamycinThe metabolism of Dapagliflozin can be increased when combined with Rifamycin.Investigational
RifapentineThe metabolism of Dapagliflozin can be increased when combined with Rifapentine.Approved, Investigational
RifaximinThe metabolism of Dapagliflozin can be increased when combined with Rifaximin.Approved, Investigational
RilpivirineThe serum concentration of Dapagliflozin can be increased when it is combined with Rilpivirine.Approved
RimexoloneThe metabolism of Dapagliflozin can be increased when combined with Rimexolone.Approved
RiociguatThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Riociguat.Approved
RisperidoneDapagliflozin may increase the hypotensive activities of Risperidone.Approved, Investigational
RitanserinRitanserin may increase the hypoglycemic activities of Dapagliflozin.Investigational
RitonavirThe metabolism of Dapagliflozin can be decreased when combined with Ritonavir.Approved, Investigational
RolapitantThe serum concentration of Dapagliflozin can be increased when it is combined with Rolapitant.Approved, Investigational
RopiniroleThe risk or severity of adverse effects can be increased when Ropinirole is combined with Dapagliflozin.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Dapagliflozin.Approved
RosoxacinThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Rosoxacin.Approved, Investigational
RosuvastatinThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Rosuvastatin.Approved
RotigotineThe risk or severity of adverse effects can be increased when Rotigotine is combined with Dapagliflozin.Approved
RucaparibThe serum concentration of Dapagliflozin can be increased when it is combined with Rucaparib.Approved, Investigational
RufloxacinThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Rufloxacin.Experimental
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Dapagliflozin.Approved
SafinamideSafinamide may increase the orthostatic hypotensive activities of Dapagliflozin.Approved, Investigational
SafrazineSafrazine may increase the orthostatic hypotensive activities of Dapagliflozin.Withdrawn
Salicylic acidSalicylic acid may increase the hypoglycemic activities of Dapagliflozin.Approved, Investigational, Vet Approved
SalinomycinThe serum concentration of Dapagliflozin can be increased when it is combined with Salinomycin.Vet Approved
SaquinavirThe metabolism of Dapagliflozin can be decreased when combined with Saquinavir.Approved, Investigational
SarafloxacinThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Sarafloxacin.Vet Approved, Withdrawn
SarilumabThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Sarilumab.Approved, Investigational
SecobarbitalSecobarbital may increase the hypotensive activities of Dapagliflozin.Approved, Vet Approved
SelegilineSelegiline may increase the orthostatic hypotensive activities of Dapagliflozin.Approved, Investigational, Vet Approved
SennosidesThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Sennosides.Approved
SertralineThe serum concentration of Dapagliflozin can be increased when it is combined with Sertraline.Approved
SetrobuvirThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Setrobuvir.Investigational
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Dapagliflozin.Approved, Vet Approved
SildenafilThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Dapagliflozin can be decreased when it is combined with Siltuximab.Approved, Investigational
Silver sulfadiazineThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Silver sulfadiazine.Approved, Vet Approved
SimeprevirThe serum concentration of Dapagliflozin can be increased when it is combined with Simeprevir.Approved
SirolimusThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Sirolimus.Approved, Investigational
SitafloxacinThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Sitafloxacin.Experimental, Investigational
Sodium phosphate, monobasicDapagliflozin may increase the nephrotoxic activities of Sodium phosphate, monobasic.Approved
Sodium sulfateThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Sodium sulfate.Approved, Vet Approved
Sodium tartrateThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Sodium tartrate.Approved
SorafenibThe serum concentration of Dapagliflozin can be increased when it is combined with Sorafenib.Approved, Investigational
SorbitolThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Sorbitol.Approved
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Dapagliflozin.Approved
SparfloxacinThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Sparfloxacin.Approved, Investigational
SpiraprilThe risk or severity of renal failure and hyperkalemia can be increased when Dapagliflozin is combined with Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Dapagliflozin.Approved
St. John's WortThe serum concentration of Dapagliflozin can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StanoloneStanolone may increase the hypoglycemic activities of Dapagliflozin.Illicit, Investigational
StanozololStanozolol may increase the hypoglycemic activities of Dapagliflozin.Approved, Vet Approved
StaurosporineThe serum concentration of Dapagliflozin can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Dapagliflozin can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Dapagliflozin.Approved, Investigational
SuccinylsulfathiazoleThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Succinylsulfathiazole.Experimental
SufentanilThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Sufentanil.Approved, Investigational
SulfacetamideThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Sulfacetamide.Approved
SulfachlorpyridazineThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Sulfachlorpyridazine.Vet Approved
SulfacytineThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Sulfacytine.Approved
SulfadiazineThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Sulfadiazine.Approved, Investigational, Vet Approved
SulfadicramideThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Sulfadicramide.Experimental
SulfadimethoxineThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Sulfadimethoxine.Approved, Vet Approved
SulfadoxineThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Sulfadoxine.Approved, Investigational
SulfaethoxypyridazineThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Sulfaethoxypyridazine.Vet Approved
SulfaguanidineThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Sulfaguanidine.Experimental
SulfaisodimidineThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Sulfaisodimidine.Experimental
SulfamazoneThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Sulfamazone.Experimental
SulfamerazineThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Sulfamerazine.Approved, Vet Approved
SulfameterThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Sulfameter.Approved
SulfamethazineThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Sulfamethazine.Approved, Investigational, Vet Approved
SulfamethizoleThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Sulfamethizole.Approved, Investigational, Vet Approved
SulfamethoxazoleThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Sulfamethoxazole.Approved
SulfamethoxypyridazineThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Sulfamethoxypyridazine.Experimental
SulfametomidineThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Sulfametomidine.Experimental
SulfametopyrazineThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Sulfametopyrazine.Approved, Withdrawn
SulfamoxoleThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Sulfamoxole.Approved
SulfanilamideThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Sulfanilamide.Approved
SulfanitranThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Sulfanitran.Vet Approved
SulfaperinThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Sulfaperin.Experimental
SulfaphenazoleThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Sulfaphenazole.Approved
SulfapyridineThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Sulfapyridine.Approved
SulfaquinoxalineThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Sulfaquinoxaline.Vet Approved
SulfasalazineSulfasalazine may increase the hypoglycemic activities of Dapagliflozin.Approved
SulfathiazoleThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Sulfathiazole.Approved, Vet Approved
SulfathioureaThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Sulfathiourea.Experimental
SulfatolamideThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Sulfatolamide.Experimental
SulfisoxazoleThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Sulfisoxazole.Approved, Vet Approved
SumatriptanThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Dapagliflozin can be increased when it is combined with Sunitinib.Approved, Investigational
SuvorexantThe serum concentration of Dapagliflozin can be increased when it is combined with Suvorexant.Approved, Investigational
TacrolimusThe serum concentration of Dapagliflozin can be increased when it is combined with Tacrolimus.Approved, Investigational
TamoxifenThe serum concentration of Dapagliflozin can be increased when it is combined with Tamoxifen.Approved
TamsulosinThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Dapagliflozin.Approved, Investigational
TapentadolThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Tapentadol.Approved
TariquidarThe serum concentration of Dapagliflozin can be increased when it is combined with Tariquidar.Investigational
Technetium Tc-99m ciprofloxacinThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Technetium Tc-99m ciprofloxacin.Investigational
TegaserodThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Tegaserod.Approved, Investigational, Withdrawn
TelaprevirThe metabolism of Dapagliflozin can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Dapagliflozin can be decreased when combined with Telithromycin.Approved
TelmisartanThe serum concentration of Dapagliflozin can be increased when it is combined with Telmisartan.Approved, Investigational
TemafloxacinThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Temafloxacin.Withdrawn
TemocaprilThe risk or severity of renal failure and hyperkalemia can be increased when Dapagliflozin is combined with Temocapril.Experimental, Investigational
TemsirolimusThe serum concentration of Dapagliflozin can be increased when it is combined with Temsirolimus.Approved
TerazosinThe risk or severity of adverse effects can be increased when Terazosin is combined with Dapagliflozin.Approved
TerfenadineThe serum concentration of Dapagliflozin can be increased when it is combined with Terfenadine.Approved, Withdrawn
TesmilifeneThe serum concentration of Dapagliflozin can be increased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Dapagliflozin can be increased when it is combined with Testosterone.Approved, Investigational
Testosterone cypionateThe serum concentration of Dapagliflozin can be increased when it is combined with Testosterone cypionate.Approved
Testosterone enanthateThe serum concentration of Dapagliflozin can be increased when it is combined with Testosterone enanthate.Approved
Testosterone propionateTestosterone propionate may increase the hypoglycemic activities of Dapagliflozin.Approved, Investigational, Vet Approved, Withdrawn
Testosterone undecanoateThe serum concentration of Dapagliflozin can be increased when it is combined with Testosterone undecanoate.Approved, Investigational
TetrandrineThe serum concentration of Dapagliflozin can be increased when it is combined with Tetrandrine.Experimental
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Dapagliflozin.Approved, Investigational, Withdrawn
ThiamylalThiamylal may increase the hypotensive activities of Dapagliflozin.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Dapagliflozin.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Dapagliflozin.Approved, Withdrawn
TianeptineTianeptine may decrease the hypoglycemic activities of Dapagliflozin.Approved, Investigational
TicagrelorThe serum concentration of Dapagliflozin can be increased when it is combined with Ticagrelor.Approved
TilidineThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Tilidine.Experimental
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Dapagliflozin.Approved
TipifarnibThe serum concentration of Dapagliflozin can be increased when it is combined with Tipifarnib.Investigational
TipranavirThe metabolism of Dapagliflozin can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Dapagliflozin.Approved, Investigational
TocilizumabThe serum concentration of Dapagliflozin can be decreased when it is combined with Tocilizumab.Approved
TolazamideDapagliflozin may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
TolazolineThe risk or severity of adverse effects can be increased when Tolazoline is combined with Dapagliflozin.Approved, Vet Approved
TolbutamideDapagliflozin may increase the hypoglycemic activities of Tolbutamide.Approved, Investigational
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Dapagliflozin.Approved, Withdrawn
ToloxatoneToloxatone may increase the orthostatic hypotensive activities of Dapagliflozin.Approved
TolvaptanThe serum concentration of Dapagliflozin can be increased when it is combined with Tolvaptan.Approved
TorasemideThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Torasemide.Approved
ToremifeneThe serum concentration of Dapagliflozin can be increased when it is combined with Toremifene.Approved, Investigational
TramadolThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Tramadol.Approved, Investigational
TrandolaprilThe risk or severity of renal failure and hyperkalemia can be increased when Dapagliflozin is combined with Trandolapril.Approved
TranylcypromineTranylcypromine may increase the orthostatic hypotensive activities of Dapagliflozin.Approved, Investigational
TrazodoneTrazodone may increase the hypoglycemic activities of Dapagliflozin.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Dapagliflozin.Approved, Investigational, Nutraceutical
TriamcinoloneThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Triamcinolone.Approved, Vet Approved
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Dapagliflozin.Approved
TrichlormethiazideThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Trichlormethiazide.Approved, Vet Approved
TrifluoperazineThe serum concentration of Dapagliflozin can be increased when it is combined with Trifluoperazine.Approved, Investigational
TriflupromazineThe serum concentration of Dapagliflozin can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimThe serum concentration of Dapagliflozin can be increased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineTrimipramine may decrease the hypoglycemic activities of Dapagliflozin.Approved
TriptorelinThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Triptorelin.Approved, Vet Approved
Trolamine salicylateTrolamine salicylate may increase the hypoglycemic activities of Dapagliflozin.Approved
TroleandomycinThe metabolism of Dapagliflozin can be decreased when combined with Troleandomycin.Approved
TrovafloxacinThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Trovafloxacin.Approved, Investigational, Withdrawn
UbidecarenoneThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Ubidecarenone.Approved, Investigational, Nutraceutical
ValinomycinThe serum concentration of Dapagliflozin can be increased when it is combined with Valinomycin.Experimental
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Dapagliflozin.Approved, Investigational
ValspodarThe serum concentration of Dapagliflozin can be increased when it is combined with Valspodar.Investigational
VelpatasvirThe serum concentration of Dapagliflozin can be increased when it is combined with Velpatasvir.Approved, Investigational
VemurafenibThe serum concentration of Dapagliflozin can be increased when it is combined with Vemurafenib.Approved
VenlafaxineThe serum concentration of Dapagliflozin can be increased when it is combined with Venlafaxine.Approved
VerapamilThe serum concentration of Dapagliflozin can be increased when it is combined with Verapamil.Approved
VinblastineThe serum concentration of Dapagliflozin can be increased when it is combined with Vinblastine.Approved
VoacamineThe serum concentration of Dapagliflozin can be increased when it is combined with Voacamine.Approved, Investigational
VorapaxarThe serum concentration of Dapagliflozin can be increased when it is combined with Vorapaxar.Approved
VoriconazoleThe metabolism of Dapagliflozin can be decreased when combined with Voriconazole.Approved, Investigational
VorinostatThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Vorinostat.Approved, Investigational
VoxilaprevirThe serum concentration of Dapagliflozin can be increased when it is combined with Voxilaprevir.Approved, Investigational
XipamideThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Xipamide.Experimental
YohimbineThe serum concentration of Dapagliflozin can be increased when it is combined with Yohimbine.Approved, Investigational, Vet Approved
ZimelidineZimelidine may increase the hypoglycemic activities of Dapagliflozin.Withdrawn
ZiprasidoneThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Ziprasidone.Approved
ZofenoprilThe risk or severity of renal failure and hyperkalemia can be increased when Dapagliflozin is combined with Zofenopril.Experimental
ZomepiracThe serum concentration of Dapagliflozin can be increased when it is combined with Zomepirac.Withdrawn
ZosuquidarThe serum concentration of Dapagliflozin can be increased when it is combined with Zosuquidar.Investigational
Food Interactions
Not Available

References

General References
  1. Obermeier M, Yao M, Khanna A, Koplowitz B, Zhu M, Li W, Komoroski B, Kasichayanula S, Discenza L, Washburn W, Meng W, Ellsworth BA, Whaley JM, Humphreys WG: In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans. Drug Metab Dispos. 2010 Mar;38(3):405-14. doi: 10.1124/dmd.109.029165. Epub 2009 Dec 8. [PubMed:19996149]
  2. Kasichayanula S, Liu X, Lacreta F, Griffen SC, Boulton DW: Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014 Jan;53(1):17-27. doi: 10.1007/s40262-013-0104-3. [PubMed:24105299]
  3. Kasichayanula S, Chang M, Hasegawa M, Liu X, Yamahira N, LaCreta FP, Imai Y, Boulton DW: Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus. Diabetes Obes Metab. 2011 Apr;13(4):357-65. doi: 10.1111/j.1463-1326.2011.01359.x. [PubMed:21226818]
External Links
KEGG Drug
D08897
PubChem Compound
9887712
PubChem Substance
175427068
ChemSpider
8063384
BindingDB
50448923
ChEBI
85078
ChEMBL
CHEMBL429910
Drugs.com
Drugs.com Drug Page
Wikipedia
Dapagliflozin
ATC Codes
A10BX09 — DapagliflozinA10BD15 — Metformin and dapagliflozinA10BD21 — Saxagliptin and dapagliflozin
AHFS Codes
  • 68:20.18 — Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors
FDA label
Download (868 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentType 2 Diabetes Mellitus2
1CompletedNot AvailableDiabetes Mellitus (DM) / Healthy Male and Female Subjects1
1CompletedNot AvailableType 2 Diabetes Mellitus9
1CompletedBasic ScienceDiabetes, Diabetes Mellitus Type 11
1CompletedBasic ScienceHealthy Volunteers4
1CompletedBasic ScienceType 2 Diabetes Mellitus2
1CompletedTreatmentDiabetes, Diabetes Mellitus Type 11
1CompletedTreatmentHealthy Volunteers1
1CompletedTreatmentType 2 Diabetes Mellitus7
1CompletedTreatmentType1diabetes1
1RecruitingBasic ScienceHealthy Volunteers1
1TerminatedNot AvailableType 2 Diabetes Mellitus1
1TerminatedDiagnosticDiabetes, NOS1
2CompletedBasic SciencePhysical Activity1
2CompletedBasic ScienceType 2 Diabetes Mellitus1
2CompletedTreatmentAsymptomatic Hyperuricemia1
2CompletedTreatmentBMI >30 kg/m21
2CompletedTreatmentDiabetes, Diabetes Mellitus Type 11
2CompletedTreatmentT2 Diabetes and Fatty Liver Disease (Non-alcoholic Origin)1
2CompletedTreatmentType 2 Diabetes Mellitus4
2Not Yet RecruitingTreatmentDiabetes, Diabetes Mellitus Type 1 / Hypoglycemia / Hypoglycemia Unawareness1
2RecruitingBasic ScienceMetabolically Healthy Controls / Type 2 Diabetes Mellitus1
2RecruitingBasic ScienceObese experiencing rapid weight loss1
2RecruitingPreventionBMI >30 kg/m2 / Prediabetic State1
2RecruitingPreventionChronic Kidney Disease (CKD) / Proteinuria1
2RecruitingPreventionDiabetes, Diabetes Mellitus Type 11
2TerminatedBasic ScienceObese experiencing rapid weight loss1
2, 3CompletedTreatmentType 2 Diabetes Mellitus2
2, 3CompletedTreatmentType 2 Diabetes Mellitus, CKD and Albuminuria / Type 2 Diabetes Mellitus, CKD3 and Albuminuria1
3Active Not RecruitingTreatmentDiabetes Mellitus (DM)1
3Active Not RecruitingTreatmentDiabetes Mellitus, Non-Insulin-Dependent / High Risk for Cardiovascular Event1
3Active Not RecruitingTreatmentDiabetes, Diabetes Mellitus Type 11
3CompletedTreatmentCardiovascular Disease (CVD) / High Blood Pressure (Hypertension) / Inadequate Glycaemic Control / Type 2 Diabetes Mellitus1
3CompletedTreatmentCardiovascular Disease (CVD) / Inadequate Glycaemic Control / Type 2 Diabetes Mellitus1
3CompletedTreatmentDiabetes Mellitus (DM)2
3CompletedTreatmentDiabetes Mellitus (DM) / Diabetes, Diabetes Mellitus Type 11
3CompletedTreatmentDiabetes, Diabetes Mellitus Type 12
3CompletedTreatmentHigh Blood Sugar / Type 2 Diabetes Mellitus1
3CompletedTreatmentHigh Blood Sugar / Type2 Diabetes1
3CompletedTreatmentHigh HbA1c Level / Inadequate Glycaemic Control / Type 2 Diabetes Mellitus1
3CompletedTreatmentInadequate Glycaemic Control / Type 2 Diabetes Mellitus / Type2 Diabetes Mellitus1
3CompletedTreatmentType 2 Diabetes Mellitus25
3Not Yet RecruitingTreatmentHeart Failure With Preserved Ejection Fraction (HFpEF)1
3Not Yet RecruitingTreatmentType 2 Diabetes Mellitus2
3RecruitingTreatmentBMI >30 kg/m2 / Polycystic Ovaries Syndrome1
3RecruitingTreatmentBMI >30 kg/m2 / Type 2 Diabetes Mellitus1
3RecruitingTreatmentChronic Heart Failure With Reduced Ejection Fraction (HFrEF)1
3RecruitingTreatmentChronic Kidney Disease (CKD)1
3RecruitingTreatmentDiabetes Prevention in Women After GDM Who Are at High-risk1
3RecruitingTreatmentDiabetes, Diabetes Mellitus Type 11
3RecruitingTreatmentType 2 Diabetes Mellitus4
3SuspendedTreatmentType 2 Diabetes Mellitus1
4Active Not RecruitingTreatmentLeft Ventricular Hypertrophy / Type 2 Diabetes Mellitus1
4Active Not RecruitingTreatmentPre-Diabetic / Prehypertension1
4Active Not RecruitingTreatmentType 2 Diabetes Mellitus2
4CompletedBasic ScienceHigh Blood Cholesterol Level / Type 2 Diabetes Mellitus1
4CompletedBasic ScienceType 2 Diabetes Mellitus1
4CompletedTreatmentBlood Pressures / BMI >30 kg/m2 / Cardiac Hypertrophy / High Blood Pressure (Hypertension) / Microalbuminuria / Type 2 Diabetes Mellitus / Vascular Stiffness1
4CompletedTreatmentDiabetes Mellitus (DM) / Heart Failure, Unspecified1
4CompletedTreatmentGlomerulosclerosis, Focal Segmental1
4CompletedTreatmentHyperglycemia Steroid-induced1
4CompletedTreatmentImpaired Fasting Glucose (IFG) / Impaired Glucose Tolerance (IGT) / Pre-Diabetic1
4CompletedTreatmentInadequate Glycaemic Control / Type 2 Diabetes Mellitus / Type2 Diabetes Mellitus1
4CompletedTreatmentIschaemic Heart Diseases / Type 2 Diabetes Mellitus1
4CompletedTreatmentMetabolic Syndromes1
4CompletedTreatmentType 2 Diabetes Mellitus7
4Enrolling by InvitationTreatmentHigh Blood Pressure (Hypertension)1
4Not Yet RecruitingNot AvailableDiabetes Mellitus (DM) / Hypoglycemic Episodes1
4Not Yet RecruitingTreatmentCarotid Artery Diseases / Coronary Artery Disease / Type 2 Diabetes Mellitus1
4Not Yet RecruitingTreatmentCoronary Disease With Diabetes Mellitus1
4Not Yet RecruitingTreatmentEvaluate Ketogenic Stress1
4Not Yet RecruitingTreatmentOral Antidiabetics / Type 2 Diabetes Mellitus1
4Not Yet RecruitingTreatmentType 2 Diabetes Mellitus3
4RecruitingBasic ScienceHepatic Glucose Metabolism1
4RecruitingBasic ScienceSkeletal Muscle Insulin Sensitivity / Type 2 Diabetes Mellitus1
4RecruitingBasic ScienceType 2 Diabetes Mellitus3
4RecruitingPreventionDiabetic Nephropathies / Type 2 Diabetes Mellitus1
4RecruitingTreatmentBMI >30 kg/m2 / Type 2 Diabetes Mellitus1
4RecruitingTreatmentCardiovascular Disease (CVD) / Type2 Diabetes1
4RecruitingTreatmentChronic Heart Failure With Preserved Systolic Function1
4RecruitingTreatmentChronic Heart Failure With Reduced Ejection Fraction (HFrEF)1
4RecruitingTreatmentDiabetes Mellitus (DM)3
4RecruitingTreatmentEndothelial Function / Type 2 Diabetes Mellitus1
4RecruitingTreatmentFasting Glucose / Glucose Excursion / Glycemic Control1
4RecruitingTreatmentHigh Blood Pressure (Hypertension) / Type 2 Diabetes Mellitus1
4RecruitingTreatmentKidney Function Tests / Type 2 Diabetes Mellitus1
4RecruitingTreatmentSteatosis, Liver / Type2 Diabetes1
4RecruitingTreatmentType 2 Diabetes Mellitus13
4Unknown StatusTreatmentType 2 Diabetes Mellitus1
4WithdrawnTreatmentType 2 Diabetes Mellitus2
Not AvailableActive Not RecruitingBasic ScienceInsulin Sensitivity / Multiple Mitochondrial Dysfunctions Syndrome1
Not AvailableCompletedNot AvailableType 2 Diabetes Mellitus2
Not AvailableCompletedBasic ScienceType 2 Diabetes Mellitus1
Not AvailableRecruitingNot AvailableCardiovascular Disease (CVD) / Type 2 Diabetes Mellitus1
Not AvailableRecruitingOtherType 2 Diabetes Mellitus1
Not AvailableRecruitingTreatmentImpaired Fasting Glucose (IFG) / Impaired Glucose Tolerance (IGT) / Type 2 Diabetes Mellitus1
Not AvailableRecruitingTreatmentType 2 Diabetes Mellitus1
Not AvailableTerminatedNot AvailableType 2 Diabetes Mellitus1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Tablet, film coatedOral10 mg
Tablet, film coatedOral5 mg
Tablet, film coatedOral10 mg/1
Tablet, film coatedOral5 mg/1
TabletOral10 mg
TabletOral5 mg
Tablet, film coatedOral
TabletOral
Tablet, film coated, extended releaseOral
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US8216180No2008-01-122028-01-12Us
US8439864No2008-03-252028-03-25Us
US6667061Yes2000-11-252020-11-25Us
US6495164No2000-05-252020-05-25Us
US6872700No2000-01-142020-01-14Us
US6956026No1998-01-072018-01-07Us
US7741269No1998-01-072018-01-07Us
US9238076No2004-04-152024-04-15Us
US8906851No2006-08-182026-08-18Us
US7612176No2005-04-132025-04-13Us
US8431685No2005-04-132025-04-13Us
US8461105No2005-04-132025-04-13Us
US8329648No2006-08-182026-08-18Us
US7456254No2005-06-302025-06-30Us
US7563871No2004-04-152024-04-15Us
US6824822No2002-10-092022-10-09Us
US6479065No2000-08-102020-08-10Us
US7223440No2001-08-312021-08-31Us
USRE44186No2003-07-312023-07-31Us
US8628799No2005-07-132025-07-13Us
US8685934No2010-05-262030-05-26Us
US8501698No2007-06-202027-06-20Us
US6414126No2000-10-042020-10-04Us
US6515117No2000-10-042020-10-04Us
US6936590No2000-10-042020-10-04Us
US9198925No2000-10-042020-10-04Us
US7919598No2009-12-162029-12-16Us
US8361972No2008-03-212028-03-21Us
US8716251No2008-03-212028-03-21Us
US7851502No2008-08-192028-08-19Us
US8221786No2008-03-212028-03-21Us
US9616028No2010-11-122030-11-12Us
US9320853No2008-03-252028-03-25Us
US8827963No2009-02-042029-02-04Us
US8712615No2010-01-182030-01-18Us
US8998876No2010-01-072030-01-07Us
US8758292No2007-11-122027-11-12Us
US8690837No2009-05-192029-05-19Us
US8721615No2010-01-182030-01-18Us

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.173 mg/mLALOGPS
logP2.52ALOGPS
logP2.11ChemAxon
logS-3.4ALOGPS
pKa (Strongest Acidic)12.57ChemAxon
pKa (Strongest Basic)-3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area99.38 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity104.93 m3·mol-1ChemAxon
Polarizability42.36 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenolic glycosides. These are organic compounds containing a phenolic structure attached to a glycosyl moiety. Some examples of phenolic structures include lignans, and flavonoids. Among the sugar units found in natural glycosides are D-glucose, L-Fructose, and L rhamnose.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbohydrates and carbohydrate conjugates
Direct Parent
Phenolic glycosides
Alternative Parents
Diphenylmethanes / Hexoses / C-glycosyl compounds / Phenoxy compounds / Phenol ethers / Alkyl aryl ethers / Chlorobenzenes / Aryl chlorides / Oxanes / Secondary alcohols
show 6 more
Substituents
Phenolic glycoside / Diphenylmethane / Hexose monosaccharide / C-glycosyl compound / Phenoxy compound / Phenol ether / Alkyl aryl ether / Chlorobenzene / Halobenzene / Aryl chloride
show 17 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
aromatic ether, organochlorine compound, C-glycosyl compound (CHEBI:85078)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
Inhibitor
General Function
Low-affinity glucose:sodium symporter activity
Specific Function
Sodium-dependent glucose transporter. Has a Na(+) to glucose coupling ratio of 1:1.Efficient substrate transport in mammalian kidney is provided by the concerted action of a low affinity high capac...
Gene Name
SLC5A2
Uniprot ID
P31639
Uniprot Name
Sodium/glucose cotransporter 2
Molecular Weight
72895.995 Da
References
  1. Obermeier M, Yao M, Khanna A, Koplowitz B, Zhu M, Li W, Komoroski B, Kasichayanula S, Discenza L, Washburn W, Meng W, Ellsworth BA, Whaley JM, Humphreys WG: In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans. Drug Metab Dispos. 2010 Mar;38(3):405-14. doi: 10.1124/dmd.109.029165. Epub 2009 Dec 8. [PubMed:19996149]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Vitamin d 24-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A1
Uniprot ID
P04798
Uniprot Name
Cytochrome P450 1A1
Molecular Weight
58164.815 Da
References
  1. Kasichayanula S, Liu X, Lacreta F, Griffen SC, Boulton DW: Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014 Jan;53(1):17-27. doi: 10.1007/s40262-013-0104-3. [PubMed:24105299]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Kasichayanula S, Liu X, Lacreta F, Griffen SC, Boulton DW: Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014 Jan;53(1):17-27. doi: 10.1007/s40262-013-0104-3. [PubMed:24105299]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Const...
Gene Name
CYP2A6
Uniprot ID
P11509
Uniprot Name
Cytochrome P450 2A6
Molecular Weight
56501.005 Da
References
  1. Kasichayanula S, Liu X, Lacreta F, Griffen SC, Boulton DW: Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014 Jan;53(1):17-27. doi: 10.1007/s40262-013-0104-3. [PubMed:24105299]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Kasichayanula S, Liu X, Lacreta F, Griffen SC, Boulton DW: Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014 Jan;53(1):17-27. doi: 10.1007/s40262-013-0104-3. [PubMed:24105299]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Kasichayanula S, Liu X, Lacreta F, Griffen SC, Boulton DW: Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014 Jan;53(1):17-27. doi: 10.1007/s40262-013-0104-3. [PubMed:24105299]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Kasichayanula S, Liu X, Lacreta F, Griffen SC, Boulton DW: Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014 Jan;53(1):17-27. doi: 10.1007/s40262-013-0104-3. [PubMed:24105299]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Retinoic acid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols. Isoform 2 lacks trans...
Gene Name
UGT1A9
Uniprot ID
O60656
Uniprot Name
UDP-glucuronosyltransferase 1-9
Molecular Weight
59940.495 Da
References
  1. Kasichayanula S, Liu X, Lacreta F, Griffen SC, Boulton DW: Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014 Jan;53(1):17-27. doi: 10.1007/s40262-013-0104-3. [PubMed:24105299]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Glucuronosyltransferase activity
Specific Function
UDPGTs are of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isozyme is active on polyhydroxylated estrogens (such as...
Gene Name
UGT2B4
Uniprot ID
P06133
Uniprot Name
UDP-glucuronosyltransferase 2B4
Molecular Weight
60512.035 Da
References
  1. Kasichayanula S, Liu X, Lacreta F, Griffen SC, Boulton DW: Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014 Jan;53(1):17-27. doi: 10.1007/s40262-013-0104-3. [PubMed:24105299]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Glucuronosyltransferase activity
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds.Its unique specificity for 3,4-catechol estrogens and estriol su...
Gene Name
UGT2B7
Uniprot ID
P16662
Uniprot Name
UDP-glucuronosyltransferase 2B7
Molecular Weight
60694.12 Da
References
  1. Kasichayanula S, Liu X, Lacreta F, Griffen SC, Boulton DW: Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014 Jan;53(1):17-27. doi: 10.1007/s40262-013-0104-3. [PubMed:24105299]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Kasichayanula S, Liu X, Lacreta F, Griffen SC, Boulton DW: Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014 Jan;53(1):17-27. doi: 10.1007/s40262-013-0104-3. [PubMed:24105299]

Drug created on March 19, 2008 10:22 / Updated on August 15, 2018 09:53